TT viral infection through blood transfusion: retrospective investigation on patients in a prospective study of post-transfusion hepatitis

Table 1 Clinical and laboratory data of 14 Patients with Post-trans fusion hepatitis

Patient	Age (yr)/gender	Peak ALT (IU/L)	Hepatitis
Unscreened Blood
SYS	58/F	1043	HCV
CLT	66/M	527	HCV
LCSG	74/F	264	HCV
PTT	76/M	109	HCV, TTV
SGM*	43/M	93	HCV
LWG	67/M	257	HCV, HGV
STS	60/M	455	HCV, HGV, TTV
CSPC**	48/F	218	HBV, CMV
CST	30/M	236	CMV, HGV
LYY	13/F	103	TTV
CSG	64/M	159	159
Screened Blood
CPL	65/F	645	CMV, TTV
HWL	65/F	541	CMV
CHL***	63/M	101	HBV

^*Patients were treated with interferon alfa 2b;

^**HBsAg ( + ), HBeAg ( - ), anti-HBe ( + ), anti-HDV ( - ); ^***HBsAg ( + ), HBeAg ( + ), anti-HBe ( - ), anti-HDV ( - ); #Positive for TTV DNA before transfusion.